Why is collecting diversity data early in the enrollment funnel important?
Per the FDA: “Clinical trials provide a crucial base of evidence for evaluating whether a medical product is safe and effective; therefore, enrollment in clinical trials should reflect the diversity of the population that is ultimately going to use the treatment.” Despite this, the majority of data collected on diversity and inclusion in clinical trials is either post-consent or post-randomization data. What that means: By the time you see you have missed your recruitment diversity goals, it is too late to take action.